Indication
In combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection

Medicine details

Medicine name:
dabrafenib (Tafinlar)
SMC ID:
SMC2131
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
11 February 2019
SMC meeting date:
08 January 2019
Patient group submission deadline:
03 December 2018